Cara Timpani

Metronomic 5-Fluorouracil Delivery Primes Skeletal Muscle for Myopathy but Does Not Cause Cachexia

Dean G Campelj, Cara A Timpani, Tabitha Cree, Aaron C Petersen, Alan Hayes, Craig A Goodman, Emma Rybalka

Journal article  |  2021  |  PHARMACEUTICALS

Skeletal myopathy encompasses both atrophy and dysfunction and is a prominent event in cancer and chemotherapy-induced cachexia. H..

Standard of care versus new-wave corticosteroids in the treatment of Duchenne muscular dystrophy: Can we do better?

Stephanie Kourakis, Cara A Timpani, Dean G Campelj, Patricia Hafner, Nuri Gueven, Dirk Fischer, Emma Rybalka

Journal article  |  2021  |  ORPHANET JOURNAL OF RARE DISEASES

BACKGROUND: Pharmacological corticosteroid therapy is the standard of care in Duchenne Muscular Dystrophy (DMD) that aims to contr..

Calming the (Cytokine) Storm: Dimethyl Fumarate as a Therapeutic Candidate for COVID-19

Cara A Timpani, Emma Rybalka

Journal article  |  2021  |  PHARMACEUTICALS

COVID-19 has rapidly spread worldwide and incidences of hospitalisation from respiratory distress are significant. While a vaccine..

Targeting Nrf2 for the treatment of Duchenne Muscular Dystrophy

Stephanie Kourakis, Cara A Timpani, Judy B de Haan, Nuri Gueven, Dirk Fischer, Emma Rybalka

Journal article  |  2021  |  REDOX BIOLOGY

Imbalances in redox homeostasis can result in oxidative stress, which is implicated in various pathological conditions including t..

Adenylosuccinic acid: a novel inducer of the cytoprotectant Nrf2 with efficacy in Duchenne muscular dystrophy

Emma Rybalka, Craig A Goodman, Dean G Campelj, Alan Hayes, Cara A Timpani

Journal article  |  2020  |  CURRENT MEDICAL RESEARCH AND OPINION

Adenylosuccinic acid (ASA) modifies Duchenne muscular dystrophy (DMD) progression in dystrophic mdx mice and human DMD patients. D..

Nitric Oxide (NO) and Duchenne Muscular Dystrophy: NO Way to Go?

Cara A Timpani, Kamel Mamchaoui, Gillian Butler-Browne, Emma Rybalka

Journal article  |  2020  |  ANTIOXIDANTS

The discordance between pre-clinical success and clinical failure of treatment options for Duchenne Muscular Dystrophy (DMD) is si..

The Paradoxical Effect of PARP Inhibitor BGP-15 on Irinotecan-Induced Cachexia and Skeletal Muscle Dysfunction

Dean G Campelj, Cara A Timpani, Aaron C Petersen, Alan Hayes, Craig A Goodman, Emma Rybalka

Journal article  |  2020  |  CANCERS

Chemotherapy-induced muscle wasting and dysfunction is a contributing factor to cachexia alongside cancer and increases the risk o..

The Failed Clinical Story of Myostatin Inhibitors against Duchenne Muscular Dystrophy: Exploring the Biology behind the Battle

Emma Rybalka, Cara A Timpani, Danielle A Debruin, Ryan M Bagaric, Dean G Campelj, Alan Hayes

Journal article  |  2020  |  CELLS

Myostatin inhibition therapy has held much promise for the treatment of muscle wasting disorders. This is particularly true for th..

Micro (mRNA) molecules could pack a big punch in the fight against neuromuscular disease

Emma Rybalka, Cara A Timpani

Journal article  |  2020  |  JOURNAL OF PHYSIOLOGY-LONDON

Dimethyl Fumarate and Its Esters: A Drug with Broad Clinical Utility?

Stephanie Kourakis, Cara A Timpani, Judy B de Haan, Nuri Gueven, Dirk Fischer, Emma Rybalka

Journal article  |  2020  |  PHARMACEUTICALS

Fumaric acid esters (FAEs) are small molecules with anti-oxidative, anti-inflammatory and immune-modulating effects. Dimethyl fuma..